Stem Cell Therapy

Regenerative Therapy Research for Type 2 Diabetes

Exploring regenerative approaches to support pancreatic beta-cell function

Stem Cell Therapy

What is Stem Cell Therapy for Diabetes?

With more than 420 million people living with type 2 diabetes worldwide, stem cell research is opening new possibilities for selected patients. Unlike standard medication-centered approaches, investigational stem cell therapies aim to support pancreatic function and improve metabolic control in carefully evaluated cases.

Umbilical cord mesenchymal stem cells (UC-MSCs) are the primary cell type used in clinical applications. These cells can differentiate into insulin-producing beta cells, rebuild insulin secretion function, and improve the pancreatic microenvironment through paracrine signaling.

Back to Therapies Contact Us

Therapeutic Benefits

Stem cell research is being studied for selected type 2 diabetes care pathways

Beta-Cell Function Support

Stem cell-based approaches are being studied for their potential to support beta-cell function and protect remaining pancreatic activity.

Improve Insulin Resistance

Regulate chronic inflammatory microenvironment, reduce inflammatory factors, and inhibit autoimmune attacks on pancreatic islets.

Reduce Complications

Simultaneously improve fatty liver, dyslipidemia, and vascular lesions, significantly reducing risk of kidney disease and retinopathy.

High Safety Profile

UC-MSCs from newborn umbilical cords have minimal immunogenicity with no serious adverse events reported globally.

Clinical Trial Results

Landmark studies from PLA General Hospital (301 Hospital) and other institutions

84.7%
Blood Glucose Control Rate
After 9 Weeks
35%
Fasting C-Peptide
Improvement
32.1%
Patients Reducing
Medication >50%
17.8%
Patients Successfully
Off Medication

China's Global Leadership

  • First to Approve & Apply

    China is the first country to achieve large-scale clinical application of stem cell therapy for Type 2 diabetes

  • 2 Drug Approvals

    Two dedicated stem cell drugs approved by NMPA for clinical trials, including HF001 gene-modified stem cell injection

  • World-Class Research

    CAS team solved three global challenges in islet organoid maturation and vascularization, published in Cell Discovery

  • Richest Clinical Data

    Over 200 clinical studies with 5000+ subjects - largest dataset globally

Stem Cell Approval

Explore Stem Cell Therapy Options

Contact us for personalized consultation on stem cell treatment for diabetes

Speak with Our Care Team